CBCT引导放疗摆位误差对中上段食管癌患者受照射剂量的影响

摘要 目的：探究锥形束CT（CBCT）引导放疗摆位误差对中上段食管癌患者受照射剂量的影响。方法：选取2017年5月～2019年5月于我院收治的60例中上段食管癌患者为研究对象,所有患者均行CBCT图像、计划CT图像采集。在患者放疗前进行CBCT扫描,将CBCT图像与计划CT图像匹配,得到左右（x轴）、头脚（y轴）、前后（z轴）三个方向的线性误差,分析出现的误差及误差的分布规律。利用模拟实际照射系统,进行模拟计划,得到实际照射靶区及正常组织受照射剂量,将其与治疗前计划比较,研究摆位误差对患者受照剂量的影响。结果：患者整体摆位误差为x轴（2.91±2.20）mm,y轴（3.89±2.17）mm,z轴（2.44±1.64）mm,x轴的MPTV为4.054 mm,y轴的MPTV为8.183 mm,z轴的MPTV为3.482 mm。模拟计划的CI、PTV的Dmin、Dmean、D95%均低于标准计划差异显著（P均＜0.05）,而模拟计划的HI低于标准计划（P＜0.05）。模拟计划的脊髓Dmax高于标准计划（P＜0.05）,而标准计划与模拟计划的双肺V20、Dmean,心脏V40差异比较无统计学意义（P均＞0.05）。结论：CBCT引导放疗摆位误差对中上段食管癌患者影响较小,提高PTV受照射剂量及治疗准确程度,对脊髓有保护效果。摆位误差对心、肺的剂量分布无明显影响。     

癔球症患者食管测压结果、心理特征分析及小剂量阿米替林的干预效果研究

摘要 目的：分析患者的食管测压结果、心理特征及小剂量阿米替林的干预效果。方法：选取2017年5月~2019年5月期间上海市静安区市北医院收治的癔球症患者137例（癔球症组）,另选取同期到上海市静安区市北医院体检的健康志愿者50例（非癔球症组）,比较两组食管测压结果、癔球症症状评分量表（GETS）评分、汉密尔顿抑郁量表-17（HAMD-17）评分、汉密尔顿焦虑量表-14（HAMA-14）评分。按随机数字表法将癔球症患者分为对照组（n=68）和研究组（n=69）,对照组给予常规治疗,研究组则在对照组的基础上联合小剂量阿米替林干预。比较对照组、研究组的临床疗效、不良反应。结果：癔球症组、非癔球症组患者食管上括约肌（UES）长度、UES残余压、食管下括约肌（LES）静息压、收缩前沿速度（CFV）、远端潜伏时间（DL）组间比较差异无统计学意义（P>0.05）;癔球症组患者UES静息压高于非癔球症组（P<0.05）。癔球症组患者GETS、HAMA-14、HAMD-17评分高于非癔球症组（P<0.05）。研究组治疗后的临床总有效率为84.06%（58/69）,高于对照组的66.18%（45/68）（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：相对于非癔球症患者,癔球症患者具有较高的UES静息压,癔球症症状及较为严重的不良情绪,采用小剂量阿米替林对癔球症进行干预可提高治疗有效率,用药安全性较好。     

Radioprotection of eye lens using protective material in neuro cone-beam computed tomography: Estimation of dose reduction rate and image quality

PurposeIn cerebral angiography, for diagnosis and interventional neuroradiology, cone-beam computed tomography (CBCT) scan is frequently performed for evaluating brain parenchyma, cerebral hemorrhage, and cerebral infarction. However, the patient’s eye lens is more frequently exposed to excessive doses in these scans than in the previous angiography and interventional neuroradiology (INR) procedures. Hence, radioprotection for the lenses is needed. This study selects the most suitable eye lens protection material for CBCT from among nine materials by evaluating the dose reduction rate and image quality.MethodsTo determine the dose reduction rate, the lens doses were measured using an anthropomorphic head phantom and a real-time dosimeter. For image quality assessment, the artifact index was calculated based on the pixel value and image noise within various regions of interest in a water phantom.ResultsThe protective materials exhibited dose reduction; however, streak artifacts were observed near the materials. The dose reduction rate and the degree of the artifact varied significantly depending on the protective material. The dose reduction rates were 14.6%, 14.2%, and 26.0% when bismuth shield: normal (bismuth shield in the shape of an eye mask), bismuth shield: separate (two separate bismuth shields), and lead goggles were used, respectively. The “separate” bismuth shield was found to be effective in dose reduction without lowering the image quality.ConclusionWe found that bismuth shields and lead goggles are suitable protective devices for the optimal reduction of lens doses.     

On the eptihermal neutron energy limit for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT): Study and impact of new energy limits

Background and purpose: Accelerator-Based Boron Neutron Capture Therapy is a radiotherapy based on compact accelerator neutron sources requiring an epithermal neutron field for tumour irradiations. Neutrons of 10 keV are considered as the maximum optimised energy to treat deep-seated tumours. We investigated, by means of Monte Carlo simulations, the epithermal range from 10 eV to 10 keV in order to optimise the maximum epithermal neutron energy as a function of the tumour depth.Methods: A Snyder head phantom was simulated and mono-energetic neutrons with 4 different incident energies were used: 10 eV, 100 eV, 1 keV and 10 keV. ¹⁰B capture rates and absorbed dose composition on every tissue were calculated to describe and compare the effects of lowering the maximum epithermal energy. The Therapeutic Gain (TG) was estimated considering the whole brain volume.Results: For tumours seated at 4 cm depth, 10 eV, 100 eV and 1 keV neutrons provided respectively 54%, 36% and 18% increase on the TG compared to 10 keV neutrons. Neutrons with energies between 10 eV and 1 keV provided higher TG than 10 keV neutrons for tumours seated up to 6.4 cm depth inside the head. The size of the tumour does not change these results.Conclusions: Using lower epithermal energy neutrons for AB-BNCT tumour irradiation could improve treatment efficacy, delivering more therapeutic dose while reducing the dose in healthy tissues. This could lead to new Beam Shape Assembly designs in order to optimise the BNCT irradiation.     

Eye lens and thyroid gland radiation exposure for patients undergoing brain computed tomography examination

This study aims to estimate the effective radiation dose and organ dose from head CT procedures. It was conducted in three main private hospitals in Khartoum State-Sudan, using Toshiba machines with 64 slices. The total number of patients included in this study was 142 patients (82 males and 60 females). The effective dose and organ dose were calculated by CT Expo software. The effective dose slightly varied among patients according to gender and age. The effective dose for female patients (5.99 mSv) was higher than that for male patients (5.84 mSv), and the pediatric dose (5.46 mSv) was lower than the adults’ dose (5.94 mSv).The dose for eye lens was found lower for male patients (89.117 mSv) than the dose for female patients (94.62) mSv). According to patients’ age: the dose received by the lens of the eye was much lower in pediatric (79.93 mSv) than the adults (92.41 mSv). The dose for thyroid in female patients (33.52 mSv) was higher than the male patients (28 mSv). The pediatric dose (28.34 mSv) was lower than the adults’ dose (30.64 mSv).Departmental imaging protocol and lack of training among hospital staff are expected to be responsible for these variations. Therefore, this study recommends that the CT technologists be trained on suitable strategies to achieve dose optimization. Moreover, patients’ doses must be monitored regularly.     

Evaluation of Garden Crop Mercury Uptake and Potential Exposure from Consumption of Garden Crops Grown on Floodplain Soils

ABSTRACT

This study investigated Hg uptake from soil into garden crops to help assess the significance of human consumption of crops as a potential route of exposure to Hg. Locations for both a floodplain and a control garden were identified within the Augusta Forestry Center near Crimora, VA, USA, which is about 16 river-km downstream from the city of Waynesboro, along the South River. The floodplain garden had measured soil Hg concentrations ranging from 4.2 to 78 mg Hg kg^?1 dry weight basis in the surface to 15-cm deep layer. A total of 139 samples from the floodplain garden from 17 different crops were analyzed for Hg. All crop samples (except for nine) had less than 0.1 μg Hg g^?1 wet weight basis (ww). Many samples were less than the method detection limit (MDL) of 0.003 μg Hg g^?1 ww. Based on the measured Hg concentrations and several conservative assumptions (e.g., Hg assumed present when less than MDL; 100% consumption from the geographical area in which study was conducted; and 100% bioavailable Hg as methyl Hg), consumption of crops with these Hg levels is not expected to be a significant route of Hg exposure.     

PROTECTIVE EFFECT OF A DONOR'S ENDOGENOUS ELECTRIC FIELDS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTE VIABILITY

Recent studies of interactions between the brain and immune system cells, as well as reports of bioeffects from artificial electromagnetic sources too weak to exert thermal effects, suggest that biophysical communication may exist between them not explained by electrochemical action. We report here that a human donor's endogenous electric fields protect his lymphocyte viability in vitro. The endogenous fields of a healthy male donor were introduced into a cell culture via a gold wire for 7 h overnight and the cells' viability compared by trypan blue exclusion, with nonexposed cells cultured similarly. Cells exposed to their donor's endogenous fields remained significantly more viable compared with unexposed cells. However, when cells were exposed to the endogenous fields of a nondonor, viability was no different from that of unexposed controls. We conclude that endogenous electric fields, observed in all living organisms, perform a previously unsuspected but important role in cellular immune system surveillance.     

Minimal Erythema Dose (MED) Testing

Ultraviolet radiation (UV) therapy is sometimes used as a treatment for various common skin conditions, including psoriasis, acne, and eczema. The dosage of UV light is prescribed according to an individual''s skin sensitivity. Thus, to establish the proper dosage of UV light to administer to a patient, the patient is sometimes screened to determine a minimal erythema dose (MED), which is the amount of UV radiation that will produce minimal erythema (sunburn or redness caused by engorgement of capillaries) of an individual''s skin within a few hours following exposure. This article describes how to conduct minimal erythema dose (MED) testing. There is currently no easy way to determine an appropriate UV dose for clinical or research purposes without conducting formal MED testing, requiring observation hours after testing, or informal trial and error testing with the risks of under- or over-dosing. However, some alternative methods are discussed.     

PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials

Pediatric phase I trials are usually carried out after the adult trial testing the same agent has started, but not completed yet. As the pediatric trial progresses, in light of the accrued interim data from the concurrent adult trial, the pediatric protocol often is amended to modify the original pediatric dose escalation design. In practice, this is done frequently in an ad hoc way, interrupting patient accrual and slowing down the trial. We developed a pediatric-continuous reassessment method (PA-CRM) to streamline this process, providing a more efficient and rigorous method to find the maximum tolerated dose for pediatric phase I oncology trials. We use a discounted joint likelihood of the adult and pediatric data, with a discount parameter controlling information borrowing between pediatric and adult trials. According to the interim adult and pediatric data, the discount parameter is adaptively updated using the Bayesian model averaging method. Numerical study shows that the PA-CRM improves the efficiency and accuracy of the pediatric trial and is robust to various model assumptions.